AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
Guide to Cyber Threat Analysis: From Data Collection to Defense Strategy
Hey there, greetings from The Bay! Let’s dive right into a burning issue here and worldwide – cybersecurity. We know with technology evolving at breakneck
